Last reviewed · How we verify
Low-dose MH002
Low-dose MH002 is a small molecule that targets the SGLT2 receptor.
Low-dose MH002 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | Low-dose MH002 |
|---|---|
| Sponsor | MRM Health NV |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, MH002 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is particularly effective in patients with type 2 diabetes. The low-dose formulation aims to minimize side effects while maintaining efficacy.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of genital infections
- Increased risk of urinary tract infections
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-dose MH002 CI brief — competitive landscape report
- Low-dose MH002 updates RSS · CI watch RSS
- MRM Health NV portfolio CI